### **1. Company Overview** Sanofi India Limited (SIL) is a leading multinational pharmaceutical company with a legacy of over 65 years in India. Operating under the parent group Sanofi, the Indian subsidiary is headquartered in Mumbai and maintains a strong presence across prevention, treatment, wellness, and patient support. It operates primarily in the **pharmaceutical business segment**, with a growing footprint in **consumer healthcare** post-demerger. The company manages a robust portfolio of innovative medicines in key therapeutic areas: - **Diabetes** (Insulin & Oral Anti-Diabetics) - **Cardiovascular (CV)** - **Central Nervous System (CNS)/Epilepsy** - **Thrombosis** - **Anti-infectives (e.g., Anti-MRSA)** - **Allergy** - **Vitamins, Minerals & Supplements (VMS)** Sanofi India exports ~12–13% of its total sales, with 60% of production from its Goa plant dedicated to international markets, reaching over 60 countries. --- ### **2. Restructuring & Strategic Focus (2025 Update)** As of **November 2025**, Sanofi India has restructured its organization to sharpen focus on **high-growth segments**, particularly **diabetes and insulin**, while optimizing operations in mature therapeutic areas through strategic partnerships. #### **Key Strategic Moves:** - **Insulin Franchise Centralization**: The company has adopted a **customer-centric model** with enhanced **digital capabilities** for its sales teams, focusing on accelerating adoption of innovative insulin products. - **Portfolio Transition for CV, CNS & OAD**: These segments have been transitioned to a **partnership-based model** leveraging third-party distributors (e.g., **Cipla** for CNS, **Emcure** for CV and OAD), enabling deeper penetration into Tier 2 and Tier 3 cities with minimal internal resource allocation. - **"India for India" Strategy**: Emphasis on **localization**—producing and tailoring global innovations (e.g., **Insutage®, Cetapin® S**, **TouStar® pen**) to meet specific Indian patient needs and improve affordability. --- ### **3. Diabetes Leadership & Growth Strategy** Diabetes remains Sanofi India’s core business, contributing **nearly half of total revenue**. The company holds the **#3 position in India’s insulin market**, with a comprehensive and growing portfolio. #### **Three-Pillar Diabetes Growth Strategy:** 1. **Segmented Portfolio** - **Lantus® (insulin glargine)**: Despite price control under NLEM, continues to show volume growth due to expanded reach and affordability programs. - **Toujeo® (U300 insulin)**: A **second-generation basal insulin** with no direct competition in India. Recorded **16–20% growth** (IQVIA MAT Dec’24), supported by real-world data and physician education on *time-in-range* and *glycemic variability*. - **Soliqua®**: A **fixed-ratio combination (FRC)** of **basal insulin + GLP-1 receptor agonist (lixisenatide)**, launched in H1 2024. Marks Sanofi’s **entry into the premix insulin segment**. - Benefits: Once-daily dosing, reduced hypoglycemia risk, and no weight gain. - Early launch performance **exceeded expectations**, indicating strong market acceptance. 2. **Market Expansion** - Focus on **early insulinization**, **public sector engagement**, and **digital outreach** (via **INTOLIFE.in**, **Sanofi Diabetes Dialogues**). - Expanded access through **e-commerce and digital platforms**, including partnerships with e-pharmacies to offer **free insulin pens** for new initiators. - Public awareness campaigns reached **over 200 million people** in 2023. 3. **AI-Powered Customer Centricity** - Deployment of **generative AI** across R&D, commercialization, and HCP engagement. - AI tools identify **next best actions** for sales teams, personalize digital content, and support **Key Opinion Leader (KOL)** engagement. - Digital platforms like **Basal Café**, **Elite Academy**, and **Neuro eZone** engage HCPs with eCME and mentorship programs. --- ### **4. Strategic Partnerships & Commercial Model** Sanofi India is leveraging partnerships to enhance **market capillarity** while focusing internal resources on **R&D and innovation**. | **Therapeutic Area** | **Partner** | **Agreement Details** | |-----------------------|------------------------|------------------------| | **Cardiovascular (CV)** | **Emcure Pharmaceuticals** | Exclusive distribution for brands like **Cardace®, Clexane®, Targocid®**, **Lasix®**, **Lasilactone®** | | **Central Nervous System (CNS)** | **Cipla Ltd** | Distribution of **Frisium®** and five other CNS brands | | **Oral Anti-Diabetics (OAD)** | **Emcure Pharmaceuticals** | Partnership for **Amaryl®** and **Cetapin®** portfolios | **Benefits**: - Access to Tier 2/3 cities via partners’ established distribution networks. - Enables **focus on core insulin innovation**. - Allows **hybrid go-to-market model** with both direct and indirect channels. --- ### **5. Innovation & Manufacturing Strength** #### **India-First Innovations:** - **TouStar® Pen**: India’s first **reusable insulin pen** with dedicated cartridges (50% more insulin than standard), reducing mix-ups and enhancing safety. - **Insutage®**: Locally produced human insulin replacing **Insuman**, enhancing **supply reliability** and localization. - **Cetapin® S**: A **locally developed, bioequivalent metformin formulation**, strengthening OAD segment. #### **Manufacturing & Supply Chain:** - **Goa Facility**: A **cGMP-compliant, WHO-approved** plant with **5 billion annual tablet capacity**. - Produces **Ramipril, Fexofenadine, Glimepiride, Sodium Valproate, Depakine**, and **Paracetamol-codeine combos**. - One of only two global sites authorized to produce **Ramipril PC granules**. - **Hybrid Model**: Uses **12 Contract Manufacturing Organizations (CMOs)** under loan licensing or full-service agreements to **scale production** and improve **cost efficiency**. - Emphasis on **digitalization**: Automated manufacturing, QR coding, paperless systems, and new formulation tech (e.g., **Wee dispersion technology** for **DePURA® Kids**). --- ### **6. Consumer Healthcare Demerger** In **June 2024**, **Sanofi Consumer Healthcare India Limited (SCHIL)** was demerged and successfully **listed on Indian stock exchanges**, aligning with Sanofi’s global strategy. - **Focus Areas**: **Allegra®** (allergies), **Combiflam®** (pain), **Avil®**, **DePURA®** (VMS). - **Turnover (FY22)**: ~₹730 crores. - **Growth Levers**: - Shift from prescription-driven to **self-care/OTC model**. - **Regulatory advocacy** to reclassify certain Rx products to OTC. - Investment in **digital marketing and e-commerce**. --- ### **7. Research, Digital & ESG Initiatives** #### **R&D & Real-World Evidence:** - **LANDMARC Study**: A **longitudinal, real-world study** on T2D progression in India, enhancing scientific credibility. - **India Charitable Access Program (InCAP)**: Longest-running humanitarian initiative in India, providing **free treatment for Lysosomal Storage Disorders**. #### **Digital & AI Transformation:** - AI used for **marketing tools**, **HCP engagement analytics**, and **sales force optimization**. - **e-KAM (electronic Key Account Management)** and digital outreach programs like **Sanofi Connect** cover **10,000+ HCPs** outside field force reach. #### **Patient Support:** - **Saath 7**: Supports **100,000+ patients annually** in insulin adherence. - **INTOLIFE.in**: Digital patient education platform focused on **insulin literacy**. - Public campaigns (e.g., #100InsulinStories, #AllergyFree clinics) boost disease awareness. --- ### **8. Competitive Positioning (as of 2024–2025)** | **Therapeutic Area** | **Market Position** | **Key Brands** | |------------------------|----------------------|----------------| | **Insulin** | #3 in market; Lantus (~30% share) | Lantus®, Toujeo®, Soliqua® | | **Cardiovascular (ACE Inhibitors)** | #1 by value, #2 overall | Cardace® | | **Anti-MRSA Agents** | #1 by value, #5 by volume | Targocid® | | **Epilepsy (Anticonvulsants)** | #1 brand | Frisium® | | **GLP-1/Insulin Combos** | First-mover advantage | Soliqua® | --- ### **11. Leadership & Governance** - **Managing Director**: **Rodolfo Hrosz** (since June 2022), bringing transformational leadership from Brazil and a focus on agility, digital excellence, and India-specific innovation. - **Board-Approved Demerger**: Enhanced strategic clarity post-separation of consumer healthcare. ---